SERPINB3 and neoplasm: In conclusion, the present study provides evidence that SerpinB3/4, both in the serum and in tumoral tissue, could be considered a useful biomarker to identify the small subgroup of CCA patients with more aggressive tumor biology and dismal prognosis.